Skip to main content
SpringerLink
Log in

Polypharmacy and Adverse Drug Reactions in the Aging Population with Heart Failure

  • Chapter
  • First Online:
Book cover Aging and Heart Failure

  • 1715 Accesses

Abstract

Normal aging is associated with numerous alterations in body composition and organ function that result in substantial changes in the absorption, distribution, metabolism, and elimination of virtually all drugs. In addition, older patients with heart failure almost invariably have multiple coexisting medical conditions for which they are receiving medications. Taken together, these factors greatly increase the risk for adverse drug events and drug interactions in older heart failure patients. This chapter reviews common adverse drug effects and drug interactions associated with heart failure therapy in older patients and discusses strategies for minimizing the risk of adverse drug events. In addition, the intersection between heart failure medications and common geriatric syndromes, including polypharmacy, falls and syncope, and fatigue and low energy, is briefly reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stegemann S, Ecker F, Maio M, et al. Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev. 2010;9:384–98.

    Article  PubMed  Google Scholar 

  2. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76.

    Article  CAS  PubMed  Google Scholar 

  3. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.

    Article  PubMed  Google Scholar 

  4. Rich MW. Heart failure in the oldest patients: The impact of comorbid conditions. Am J Geriatr Cardiol. 2005;14:134–41.

    Article  PubMed  Google Scholar 

  5. Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald’s heart disease. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 1928.

    Google Scholar 

  6. Stevens LA, Levey AS. Chronic kidney disease in the elderly − how to assess risk. N Engl J Med. 2005;352:2122–4.

    Article  CAS  PubMed  Google Scholar 

  7. Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc. 2009;57:335–40.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG. The aging kidney. Kidney Int. 2008;74(6):710–20.

    Article  CAS  PubMed  Google Scholar 

  9. Kenney WL, Chiu P. Influence of age on thirst and fluid intake. Med Sci Sports Exerc. 2001;33:1524–32.

    Article  CAS  PubMed  Google Scholar 

  10. Shem S. House of God. New York: Random House, Inc.; 1979.

    Google Scholar 

  11. Steinman MA, Hanlon JT. Managing medications in clinically complex elders. “There’s got to be a happy medium”. JAMA. 2010;304:1592–601.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–52.

    Article  CAS  PubMed  Google Scholar 

  13. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial − the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–7.

    Article  CAS  PubMed  Google Scholar 

  14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.

    Article  CAS  PubMed  Google Scholar 

  15. Levey AS, Bosch JP, Lewis JB. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new predication equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–70.

    Article  CAS  PubMed  Google Scholar 

  16. Khan J, Goodlin SJ. Heart failure treatment in the elderly. Expert Rev Cardiovasc Ther. 2011;9:1171–9.

    Article  Google Scholar 

  17. Massie BM, Armtrong PW, Cleland JG, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med. 2001;161:165–71.

    Article  CAS  PubMed  Google Scholar 

  18. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–8.

    Article  CAS  PubMed  Google Scholar 

  19. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.

    Article  CAS  PubMed  Google Scholar 

  20. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148:971–8.

    Article  CAS  PubMed  Google Scholar 

  21. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med. 2007;357:1229–37.

    Article  CAS  PubMed  Google Scholar 

  22. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119:e391–479.

    Article  PubMed  Google Scholar 

  23. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346–54.

    Article  PubMed  Google Scholar 

  24. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107:490–7.

    Article  PubMed  Google Scholar 

  25. Hanratty CG, McGlinchey P, Johnston GD, Passmore AP. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging. 2000;17:353–62.

    Article  CAS  PubMed  Google Scholar 

  26. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Rich MW, McSherry F, Williford WO, Yusuf S. Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001;38:806–13.

    Article  CAS  PubMed  Google Scholar 

  28. Weil J, Sen Gupta R, Herfarth H. Nonocclusive mesenteric ischemia induced by digitalis. Int J Colorectal Dis. 2004;19:277–80.

    Article  PubMed  Google Scholar 

  29. Schaefer DC, Cheskin LJ. Constipation in the elderly. Am Fam Physician. 1998;58:907–14.

    CAS  PubMed  Google Scholar 

  30. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥ 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87:413–9.

    Article  CAS  PubMed  Google Scholar 

  31. Heart Failure Society of America. 2010 Comprehensive Heart Failure Practice Guidelines. Heart failure in patients with preserved ejection fraction. J Card Fail. 2010;16:e73–97.

    Article  Google Scholar 

  32. Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636–44.

    Article  PubMed  Google Scholar 

  33. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12:485–94.

    Article  CAS  PubMed  Google Scholar 

  34. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:13S–24.

    Article  CAS  PubMed  Google Scholar 

  35. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777–84.

    Article  CAS  PubMed  Google Scholar 

  36. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298:1312–22.

    Article  CAS  PubMed  Google Scholar 

  37. Shirolkar SC, Fiuzat M, Becker RC. Dronedarone and vitamin K antagonists: a review of drug-drug interactions. Am Heart J. 2010;160:577–82.

    Article  CAS  PubMed  Google Scholar 

  38. Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol. 2002;90:663–5.

    Article  CAS  PubMed  Google Scholar 

  39. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–78.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Cohen PA, Ernst E. Safety of herbal supplements: a guide for cardiologists. Cardiovasc Ther. 2010;28:246–53.

    Article  PubMed  Google Scholar 

  41. Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: Impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail. 2011;17:217–23.

    Article  PubMed  Google Scholar 

  42. Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc. 2002;50:26–34.

    Article  PubMed  Google Scholar 

  43. American Geriatrics Society 2012 Beers criteria update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.

    Article  Google Scholar 

  44. Ronchon PA, Gurwitz JH. Optimizing drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096–9.

    Article  Google Scholar 

  45. Wolf MS, Curtis LM, Waite K, et al. Helping patients simplify and safely use complex prescription regimens. Arch Intern Med. 2011;171:300–5.

    Article  PubMed  Google Scholar 

  46. Fulmer TT, Feldman PH, Kim TS, et al. An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nurs. 1999;25:6–14.

    CAS  PubMed  Google Scholar 

  47. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part 1: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139–46.

    Article  PubMed  Google Scholar 

  48. Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med. 2007;120:841–7.

    Article  PubMed  Google Scholar 

  49. Poluri A, Mores J, Cook DB, Findley TW, Cristian A. Fatigue in the elderly population. Phys Med Rehabil Clin N Am. 2005;16:91–108.

    Article  PubMed  Google Scholar 

  50. Wick JY, LaFleur J. Fatigue: implications for the elderly. Consult Pharm. 2007;22:566–78.

    Article  PubMed  Google Scholar 

  51. Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol. 1989;13:656–61.

    Article  CAS  PubMed  Google Scholar 

  52. Choi JY, Morris JC, Hsu CY. Aging and cerebrovascular disease. Neurol Clin. 1998;16:687–711.

    Article  CAS  PubMed  Google Scholar 

  53. Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U. Hypertension and cognitive function in the elderly. Am J Ther. 2007;14:533–54.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington University School of Medicine, 660 S. Euclid Avenue, 8086, St. Louis, MO, 63110, USA

    Michael W. Rich MD

  2. Cheyenne Cardiology Associates, Cheyenne, WY, USA

    William J. Nienaber MD

Authors
  1. Michael W. Rich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. Nienaber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Rich MD .

Editor information

Editors and Affiliations

  1. Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta and Hospitals, Edmonton, Alberta, Canada

    Bodh I. Jugdutt

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rich, M.W., Nienaber, W.J. (2014). Polypharmacy and Adverse Drug Reactions in the Aging Population with Heart Failure. In: Jugdutt, B. (eds) Aging and Heart Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0268-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0268-2_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0267-5

  • Online ISBN: 978-1-4939-0268-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation